Related Experiment Videos
Experimental work with anabolics in autoimmunity models
Abstract:
19-nortestosterone (nandrolone) or its decanoate was tested in six animal models for autoimmune disease. The compound was found capable of inhibiting the development of disease symptoms or the deterioration of certain immune parameters in three out of five models of spontaneous autoimmune disease: NZB/NZW F1 (NZB/W) mice (lupus glomerulonephritis, Sjögren's disease-like syndrome), NZB (lupus glomerulonephritis, autoimmune haemolytic anaemia) and OS chickens (thyroiditis). No effect of the compound was seen in MRL lpr/lpr mice (lupus glomerulonephritis, lymphoproliferative disease) and in BB rats (insulin-dependent diabetes mellitus; IDDM). Nandrolone decanoate also seems to be active in myasthenia gravis evoked in rats immunised with acetylcholine receptor but further experiments are necessary to confirm this. In a first experiment also ethylestrenol was found to give favourable effects in the model.
Insights
Nandrolone decanoate showed promise in treating autoimmune diseases in animal models, inhibiting symptoms in lupus and thyroiditis. Further research is needed to confirm its efficacy in other conditions like myasthenia gravis.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Autoimmune diseases involve the immune system attacking the body's own tissues.
- Anabolic-androgenic steroids, like nandrolone, have immunomodulatory effects.
- Investigating therapeutic potential of nandrolone in autoimmune disease models is crucial.
Purpose of the Study:
- To evaluate the efficacy of 19-nortestosterone (nandrolone) and nandrolone decanoate in preclinical models of autoimmune diseases.
- To assess the impact of nandrolone on disease progression and immune parameters in various spontaneous and induced autoimmune conditions.
Main Methods:
- Six distinct animal models of autoimmune disease were utilized, including NZB/NZW F1 mice, NZB mice, OS chickens, MRL lpr/lpr mice, BB rats, and rats with experimentally induced myasthenia gravis.
- Nandrolone decanoate was administered to assess its effects on disease development and immune function.
- Ethylestrenol was also tested in an initial experiment.
Main Results:
- Nandrolone decanoate demonstrated inhibitory effects on disease symptoms and immune deterioration in three of five spontaneous autoimmune models: NZB/W mice (lupus glomerulonephritis, Sjögren's disease-like syndrome), NZB mice (lupus glomerulonephritis, autoimmune hemolytic anemia), and OS chickens (thyroiditis).
- No significant effects were observed in MRL lpr/lpr mice (lupus glomerulonephritis, lymphoproliferative disease) and BB rats (insulin-dependent diabetes mellitus).
- Preliminary data suggests potential activity of nandrolone decanoate in experimental myasthenia gravis, requiring further investigation. Ethylestrenol also showed favorable effects in initial tests.
Conclusions:
- Nandrolone decanoate exhibits therapeutic potential in specific autoimmune conditions, notably lupus and thyroiditis, as evidenced by animal model studies.
- The compound's efficacy varies across different autoimmune disease models, highlighting the need for targeted therapeutic strategies.
- Further research is warranted to elucidate the mechanisms of action and confirm the therapeutic benefits of nandrolone decanoate in autoimmune diseases, including myasthenia gravis.